

1 XAVIER BECERRA  
Attorney General of California  
2 ALEXANDRA M. ALVAREZ  
Supervising Deputy Attorney General  
3 RYAN J. MCEWAN  
Deputy Attorney General  
4 State Bar No. 285595  
1300 I Street, Suite 125  
5 P.O. Box 944255  
Sacramento, CA 94244-2550  
6 Telephone: (916) 210-7548  
Facsimile: (916) 327-2247  
7 *Attorneys for Complainant*

8  
9 **BEFORE THE**  
**MEDICAL BOARD OF CALIFORNIA**  
10 **DEPARTMENT OF CONSUMER AFFAIRS**  
**STATE OF CALIFORNIA**

11  
12 In the Matter of the Accusation Against:

Case No. 800-2017-038585

13 **Caroline Little Cribari, M.D.**  
14 **1815 Cannery Loop**  
**Davis, CA 95616-1358**

**A C C U S A T I O N**

15 **Physician's and Surgeon's Certificate**  
16 **No. A 70686,**

Respondent.

17  
18 Complainant alleges:

19 **PARTIES**

20 1. William Prasifka (Complainant) brings this Accusation solely in his official capacity  
21 as the Executive Director of the Medical Board of California, Department of Consumer Affairs  
22 (Board).

23 2. On or about January 14, 2000, the Medical Board issued Physician's and Surgeon's  
24 Certificate No. A 70686 to Caroline Little Cribari, M.D. (Respondent). The Physician's and  
25 Surgeon's Certificate was in full force and effect at all times relevant to the charges brought  
26 herein and will expire on September 30, 2021, unless renewed.

27 ///

28 ///

**JURISDICTION**

1  
2           3.     This Accusation is brought before the Board, under the authority of the following  
3 laws. All section references are to the Business and Professions Code (Code) unless otherwise  
4 indicated.

5           4.     Section 2227 of the Code provides that a licensee who is found guilty under the  
6 Medical Practice Act may have his or her license revoked, suspended for a period not to exceed  
7 one year, placed on probation and required to pay the costs of probation monitoring, or such other  
8 action taken in relation to discipline as the Board deems proper.

9           5.     Section 2234 of the Code, states:

10                   “The board shall take action against any licensee who is charged with  
11 unprofessional conduct. In addition to other provisions of this article, unprofessional  
12 conduct includes, but is not limited to, the following:

13                           “(a) Violating or attempting to violate, directly or indirectly, assisting in or  
14 abetting the violation of, or conspiring to violate any provision of this chapter.

15                           “(b) Gross negligence.

16                           “(c) Repeated negligent acts. To be repeated, there must be two or more  
17 negligent acts or omissions. An initial negligent act or omission followed by a  
18 separate and distinct departure from the applicable standard of care shall constitute  
19 repeated negligent acts.

20                           “(1) An initial negligent diagnosis followed by an act or omission medically  
21 appropriate for that negligent diagnosis of the patient shall constitute a single  
22 negligent act.

23                           “(2) When the standard of care requires a change in the diagnosis, act, or  
24 omission that constitutes the negligent act described in paragraph (1), including, but  
25 not limited to, a reevaluation of the diagnosis or a change in treatment, and the  
26 licensee’s conduct departs from the applicable standard of care, each departure  
27 constitutes a separate and distinct breach of the standard of care.

28                           “...”



1           11. On or about November 16, 2017, the Board received an online complaint from Dr.  
2 N.F., a psychiatrist with a valid California Physician's and Surgeon's Certificate, regarding an  
3 encounter involving Patient A and Respondent. According to the complaint, on or about  
4 November 12, 2017, Patient A arrived at the University of California, Davis Medical Center  
5 Emergency Department for an emergency psychiatric evaluation. During the encounter, Dr. N.F.  
6 evaluated Patient A and elicited that Respondent, a relative, had initiated a prescription of the  
7 antidepressant medication, nortriptyline, approximately two weeks earlier at 10 mg/day and  
8 increased the dose to 20 mg/day approximately one week before arriving at the Emergency  
9 Department. When Dr. N.F. asked Respondent about this prescribing practice, Respondent  
10 acknowledged that she prescribed and increased this medication. She further stated that Patient A  
11 had been assessed by physician, Dr. A.K., who recommended the medication and gave  
12 Respondent the option of prescribing it herself.

13           12. Dr. N.F. further reported to the Board that, on or about November 13, 2017, he spoke  
14 to Dr. A.K. to coordinate care as Patient A was still in the Emergency Department at that time.  
15 Dr. A.K. stated that his last assessment of Patient A occurred in May 2017; that he was not aware  
16 of adding nortriptyline to Patient A's medications; and that he did not recall giving Respondent  
17 the option of prescribing medication herself.

18           13. When the Board investigated the above complaint, Respondent admitted to Board  
19 investigators that she wrote the nortriptyline prescription for Patient A that led to hospitalization  
20 in November 2017. She maintained, however, that she did so in collaboration with Dr. A.K. and  
21 that he gave her the option of prescribing the medication herself. Respondent also admitted that  
22 she prescribed to Patient A in other instances but that she only refilled or continued medications  
23 that were established by Patient A's physicians. Respondent further stated that she did not  
24 maintain medical records for Patient A (or Patient B who is described below).

25           14. During the investigation, the Board acquired CURES reports<sup>2</sup> and certified pharmacy  
26 records showing that Respondent prescribed medication on a regular basis to Patient A from at

27           <sup>2</sup> Controlled Substance Utilization Review and Evaluation System (CURES) is a database  
28 of Schedule II, III and IV Controlled Substance prescriptions dispensed in California serving the  
public health, regulatory oversight agencies, and law enforcement.

1 least December 27, 2011 through the period of data collection—the last prescription was filled on  
2 November 3, 2019. These records show that Respondent prescribed a variety of non-psychotropic  
3 and psychotropic medications, including controlled substances, to Patient A throughout that time  
4 (and after the hospitalization in November 2017). The records further show that Respondent not  
5 only continued prescriptions started by other physicians but she initiated new prescriptions on  
6 more than one occasion.

7 15. For example, the CURES reports and certified pharmacy records obtained by the  
8 Board reveal that Respondent wrote at least 124 prescriptions for Patient A in the roughly 8-year  
9 period from December 2011 to November 2019. Respondent wrote approximately 70  
10 prescriptions for Intuniv (guanfacine extended-release),<sup>3</sup> 9 prescriptions for aripiprazole, 4  
11 prescriptions for lithium carbonate, and 1 prescription for nortriptyline (on October 25, 2017). In  
12 terms of controlled substances, Respondent wrote at least 17 prescriptions for Patient A for  
13 amphetamine/dextroamphetamine immediate release and at least 13 prescriptions for Adderall  
14 XR (amphetamine/dextroamphetamine extended-release),<sup>4</sup> together approximately 3,360 tablets  
15 in total. Respondent also wrote (and sometimes initiated new) prescriptions for Patient A for  
16 several more non-psychotropic, non-controlled medications.

17 16. Medical records obtained by the Board confirm that Dr. A.K.'s last contact with  
18 Patient A and Respondent occurred on May 8, 2017, more than five months before the  
19 nortriptyline prescription and more than six months before the related hospitalization in  
20 November 2017.<sup>5</sup> At that May visit, Dr. A.K. documented a plan for an annual follow up. The  
21 medical records provided by Dr. A.K. do not include any reference to nortriptyline, let alone a  
22

23 <sup>3</sup> Guanfacine extended release (generic name for the drug Intuniv) is a non-stimulant  
medication approved to treat attention deficit hyperactivity disorder in children and adolescents.

24 <sup>4</sup> Amphetamine/dextroamphetamine (generic name for the drug Adderall and also known  
as amphetamine salts) is a combination drug containing four salts of the two enantiomers of  
25 amphetamine, a Central Nervous System stimulant of the phenethylamine class.  
Amphetamine/dextroamphetamine is used to treat attention deficit hyperactivity disorder and  
26 narcolepsy but can be used recreationally as an aphrodisiac and euphoriant. Adderall is habit  
forming. Amphetamine/dextroamphetamine is a Schedule II Controlled Substance pursuant to  
27 Code of Federal Regulations Title 21 section 1308.12(d) and a dangerous drug pursuant to  
Business and Professions Code section 4022.

28 <sup>5</sup> Prior to the May 2017 visit, Dr. A.K. saw Patient A only once in 2016 (March 3, 2016)  
and once in 2015 (February 2, 2015).

1 conversation between Dr. A.K. and Respondent about her prescribing that medication. Dr. A.K.  
2 later told a Board investigator that he did not recall prescribing nortriptyline to Patient A.

3 17. At the Board Interview, Respondent admitted that it was inappropriate to prescribe  
4 controlled substances to Patient A.

5 18. Respondent committed gross negligence in the care and treatment of Patient A, which  
6 included, but is not limited to the following:

7 A. Respondent established a physician-patient relationship of at least seven-years  
8 duration with Patient A;

9 B. Respondent initiated new treatment and continued previous treatment by  
10 prescribing medication, including psychotropic medication, to Patient A; and

11 C. Respondent prescribed controlled substances to Patient A beyond an  
12 emergency.

13 Patient B

14 19. Patient B and Respondent are family relatives. At all times relevant to the charges  
15 brought herein, Patient B has been a minor.

16 20. The Board investigation revealed that Respondent prescribed medication regularly to  
17 Patient B from at least April 24, 2013 to June 12, 2019. The CURES reports and certified  
18 pharmacy records show that Respondent prescribed a variety of non-psychotropic and  
19 psychotropic medications, including controlled substances, to Patient B. The records further show  
20 that Respondent not only continued prescriptions started by other physicians but also initiated  
21 new prescriptions on more than one occasion.

22 21. For example, the CURES reports and certified pharmacy records obtained by the  
23 Board show that Respondent wrote 17 prescriptions for Patient B in a roughly 6-year period.  
24 From July 14, 2013 to January 24, 2014, Respondent wrote at least 5 prescriptions for  
25 amphetamine/dextroamphetamine immediate release and at least 4 prescriptions for Adderall XR  
26 (amphetamine/dextroamphetamine extended-release), together approximately 750 tablets of  
27 controlled substances. Respondent also wrote prescriptions for Patient B for several more non-  
28 psychotropic, non-controlled medications.



1 alleged in paragraphs 8 through 25, above, which are hereby incorporated by reference and  
2 realleged as if fully set forth herein.

3 **PRAYER**

4 WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,  
5 and that following the hearing, the Medical Board of California issue a decision:


6 1. Revoking or suspending Physician's and Surgeon's Certificate No. A 70686, issued  
7 to Caroline Little Cribari, M.D.;

8 2. Revoking, suspending or denying approval of Caroline Little Cribari, M.D.'s  
9 authority to supervise physician assistants and advanced practice nurses;

10 3. Ordering Caroline Little Cribari, M.D., if placed on probation, to pay the Board the  
11 costs of probation monitoring; and

12 4. Taking such other and further action as deemed necessary and proper.

13  
14 DATED: **JUL 23 2020**

  
\_\_\_\_\_  
WILLIAM PRASIFKA  
Executive Director  
Medical Board of California  
Department of Consumer Affairs  
State of California  
*Complainant*

15  
16  
17  
18  
19 SA2020301852  
20 34196659\_2.docx